Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial.

ABSTRACT:

Aims

Aspirin is widely used in cardiovascular disease prevention but is also associated with an increased risk of bleeding. The net effect of aspirin on dementia and cognitive impairment is uncertain.

Methods and results

In the ASCEND trial, 15 480 people from the UK with diabetes and no history of cardiovascular disease were randomized to aspirin 100 mg daily or matching placebo for a mean of 7.4 years. The 15 427 ASCEND participants with no recorded dementia prior to baseline were included in this cognitive study with a primary pre-specified outcome of 'broad dementia', comprising dementia, cognitive impairment, or confusion. This was ascertained through participant, carer, or general practitioner report or hospital admission diagnosis, by 31 March 2019 (∼2 years beyond th

SUBMITTER: Parish S 

PROVIDER: S-EPMC9242621 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature